Key terms
About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BMY news
Today
7:40am ET
Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)
Today
5:25am ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Today
5:19am ET
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
Today
4:47am ET
Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Yesterday
12:34pm ET
Massive Job Cuts Send Bristol-Myers Squibb (NYSE:BMY) Stock Into Tailspin
Yesterday
8:02am ET
Bristol-Myers Squibb Q1 Earnings Call Strategy Insights
Yesterday
7:32am ET
Purple Biotech’s Phase 2 pancreatic cancer study selected as presentation
Yesterday
7:04am ET
Bristol Myers lowers FY24 adjusted EPS view to 40c-70c, consensus 65c
Yesterday
7:02am ET
Bristol Myers reports Q1 adjusted EPS ($4.40), consensus ($4.44)
Yesterday
5:35am ET
Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates
Apr 24
8:25pm ET
Notable companies reporting before tomorrow’s open
Apr 24
2:22pm ET
Notable companies reporting before tomorrow’s open
Apr 22
7:18am ET
Bristol Myers price target lowered to $52 from $55 at Cantor Fitzgerald
Apr 22
7:02am ET
Bristol Myers and Cellares sign $380M agreement for CAR T cell therapies
Apr 22
7:01am ET
Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
Apr 18
6:18am ET
Bristol Myers price target raised to $52 from $51 at Wells Fargo
Apr 18
6:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
Apr 12
6:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)
Apr 12
5:25am ET
Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio
Apr 08
11:33am ET
Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months
Apr 08
5:47am ET
Bristol-Myers Squibb’s Hold Rating: Balancing KarXT’s Efficacy and Safety with Financial Uncertainties
Apr 07
6:44am ET
Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT
Apr 07
6:34am ET
Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial
Apr 05
9:08am ET
Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
Apr 03
4:03pm ET
Standard BioTools announces multi-year agreement with Bristol Myers
Apr 03
5:56am ET
Bristol Myers: European Commission expands approval of Reblozyl
Apr 03
5:16am ET
Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
Apr 01
7:39am ET
Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
Mar 31
5:25am ET
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024
Mar 29
8:30am ET
Bristol Myers ends collaboration agreement with Molecular Templates
Mar 28
5:20pm ET
Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial
Mar 28
4:15pm ET
Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS
Apr 14
10:16am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
Apr 11
9:10am ET
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
Apr 08
7:00am ET
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
Apr 06
3:02pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
Apr 02
2:30pm ET
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Mar 29
11:26am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
Mar 29
9:45am ET
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Mar 21
1:28pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
Mar 14
8:15am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
BMY Financials
Key terms
Ad Feedback
BMY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BMY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range